Qiming Venture Partners has recently led a RMB200 million (US$29.18 million) new round in Chinese AI medical company Shukun Technology.
ThunderSoft, Everest Capital and SPD Silicon Valley Bank also participated in the new round.
The latest round is just after the completion of a RMB200 million series B1 financing round in June this year, led by BOC International, with participation from CCB International Healthcare Fund and previous investors including China Creation Ventures, Huagai Capital.
In terms of products, Shukun Technology has successively launched coronary CTA structured imaging report, functional evaluation product CT-FFR, pericoronary fat FAI evaluation system, calcification score intelligent report, aortic dissection surgery planning, virtual stent, postoperative evaluation and other products, realizing the comprehensive intelligence of cardiovascular diagnosis and treatment.
In July of this year, Beijing-based Shukun Technology launched a "digital brain" product for stroke, which can accurately locate the lesion and provide complete imaging-assisted diagnosis including hemorrhage, ischemia, aneurysm, and CTP related parameters, shortening the emergency time and improving the efficiency of patient treatment.
The company raised a RMB100 million (US$15 million) series A round in 2018 led by Huagai Capital and Morningside Venture Capital, and a RMB22 million (US$3 million) angel round from Marathon Venture Partners in 2017.